JP2016505138A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016505138A5 JP2016505138A5 JP2015551784A JP2015551784A JP2016505138A5 JP 2016505138 A5 JP2016505138 A5 JP 2016505138A5 JP 2015551784 A JP2015551784 A JP 2015551784A JP 2015551784 A JP2015551784 A JP 2015551784A JP 2016505138 A5 JP2016505138 A5 JP 2016505138A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- target
- activatable antibody
- antibody
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 9
- 238000000034 method Methods 0.000 claims 8
- 108091005804 Peptidases Proteins 0.000 claims 6
- 239000004365 Protease Substances 0.000 claims 6
- 239000012472 biological sample Substances 0.000 claims 6
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 5
- 229920001184 polypeptide Polymers 0.000 claims 5
- 102000004196 processed proteins & peptides Human genes 0.000 claims 5
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 239000003795 chemical substances by application Substances 0.000 claims 4
- 239000012634 fragment Substances 0.000 claims 3
- 125000006850 spacer group Chemical group 0.000 claims 3
- 150000001413 amino acids Chemical class 0.000 claims 2
- 239000000427 antigen Substances 0.000 claims 2
- 102000036639 antigens Human genes 0.000 claims 2
- 108091007433 antigens Proteins 0.000 claims 2
- 239000003153 chemical reaction reagent Substances 0.000 claims 2
- 239000002872 contrast media Substances 0.000 claims 2
- 238000010494 dissociation reaction Methods 0.000 claims 2
- 230000005593 dissociations Effects 0.000 claims 2
- 239000000523 sample Substances 0.000 claims 2
- 239000000758 substrate Substances 0.000 claims 2
- JARGNLJYKBUKSJ-KGZKBUQUSA-N (2r)-2-amino-5-[[(2r)-1-(carboxymethylamino)-3-hydroxy-1-oxopropan-2-yl]amino]-5-oxopentanoic acid;hydrobromide Chemical compound Br.OC(=O)[C@H](N)CCC(=O)N[C@H](CO)C(=O)NCC(O)=O JARGNLJYKBUKSJ-KGZKBUQUSA-N 0.000 claims 1
- 108010075254 C-Peptide Proteins 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims 1
- 102000035195 Peptidases Human genes 0.000 claims 1
- 206010039509 Scab Diseases 0.000 claims 1
- -1 chromophore Substances 0.000 claims 1
- 239000000975 dye Substances 0.000 claims 1
- 239000007850 fluorescent dye Substances 0.000 claims 1
- 108010044804 gamma-glutamyl-seryl-glycine Proteins 0.000 claims 1
- 108700026078 glutathione trisulfide Proteins 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 238000011065 in-situ storage Methods 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- 230000000873 masking effect Effects 0.000 claims 1
- 238000005259 measurement Methods 0.000 claims 1
- 229910021645 metal ion Inorganic materials 0.000 claims 1
Applications Claiming Priority (17)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361749212P | 2013-01-04 | 2013-01-04 | |
| US201361749220P | 2013-01-04 | 2013-01-04 | |
| US61/749,212 | 2013-01-04 | ||
| US61/749,220 | 2013-01-04 | ||
| US201361749529P | 2013-01-07 | 2013-01-07 | |
| US201361749486P | 2013-01-07 | 2013-01-07 | |
| US61/749,486 | 2013-01-07 | ||
| US61/749,529 | 2013-01-07 | ||
| US201361755810P | 2013-01-23 | 2013-01-23 | |
| US61/755,810 | 2013-01-23 | ||
| US201361763237P | 2013-02-11 | 2013-02-11 | |
| US61/763,237 | 2013-02-11 | ||
| US201361830940P | 2013-06-04 | 2013-06-04 | |
| US61/830,940 | 2013-06-04 | ||
| US201361897659P | 2013-10-30 | 2013-10-30 | |
| US61/897,659 | 2013-10-30 | ||
| PCT/US2014/010216 WO2014107599A2 (en) | 2013-01-04 | 2014-01-03 | Compositions and methods for detecting protease activity in biological systems |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019190445A Division JP7001652B2 (ja) | 2013-01-04 | 2019-10-17 | 生体系におけるプロテアーゼ活性を検出するための組成物及び方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016505138A JP2016505138A (ja) | 2016-02-18 |
| JP2016505138A5 true JP2016505138A5 (OSRAM) | 2017-02-09 |
| JP6605957B2 JP6605957B2 (ja) | 2019-11-13 |
Family
ID=51062553
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015551784A Active JP6605957B2 (ja) | 2013-01-04 | 2014-01-03 | 生体系におけるプロテアーゼ活性を検出するための組成物及び方法 |
| JP2019190445A Active JP7001652B2 (ja) | 2013-01-04 | 2019-10-17 | 生体系におけるプロテアーゼ活性を検出するための組成物及び方法 |
| JP2021209234A Active JP7223832B2 (ja) | 2013-01-04 | 2021-12-23 | 生体系におけるプロテアーゼ活性を検出するための組成物及び方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019190445A Active JP7001652B2 (ja) | 2013-01-04 | 2019-10-17 | 生体系におけるプロテアーゼ活性を検出するための組成物及び方法 |
| JP2021209234A Active JP7223832B2 (ja) | 2013-01-04 | 2021-12-23 | 生体系におけるプロテアーゼ活性を検出するための組成物及び方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (4) | US10261083B2 (OSRAM) |
| EP (1) | EP2941643A4 (OSRAM) |
| JP (3) | JP6605957B2 (OSRAM) |
| CN (2) | CN105008918A (OSRAM) |
| AU (2) | AU2014204015A1 (OSRAM) |
| CA (1) | CA2896282C (OSRAM) |
| HK (1) | HK1210831A1 (OSRAM) |
| RU (1) | RU2015132436A (OSRAM) |
| WO (1) | WO2014107599A2 (OSRAM) |
Families Citing this family (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2403964B1 (en) | 2009-03-02 | 2021-09-08 | Massachusetts Institute of Technology | Methods and products for in vivo enzyme profiling |
| US10006916B2 (en) | 2011-03-15 | 2018-06-26 | Massachusetts Institute Of Technology | Multiplexed detection with isotope-coded reporters |
| GB201203442D0 (en) | 2012-02-28 | 2012-04-11 | Univ Birmingham | Immunotherapeutic molecules and uses |
| SG11201408554QA (en) | 2012-06-22 | 2015-02-27 | Cytomx Therapeutics Inc | Anti-jagged 1/jagged 2 cross-reactive antibodies, activatable anti-jagged antibodies and methods of use thereof |
| HK1210831A1 (en) | 2013-01-04 | 2016-05-06 | Cytomx Therapeutics Inc. | Compositions and methods for detecting protease activity in biological systems |
| KR20160018579A (ko) | 2013-06-04 | 2016-02-17 | 싸이톰스 테라퓨틱스, 인크. | 활성화가능 항체를 접합하기 위한 조성물 및 방법 |
| CN118010994A (zh) | 2013-06-07 | 2024-05-10 | 麻省理工学院 | 基于亲和力检测配体编码的合成性生物标记物 |
| RU2727836C2 (ru) * | 2013-07-25 | 2020-07-24 | Сайтомкс Терапьютикс, Инк. | Мультспецифические антитела, мультспецифические активируемые антитела и способы их применения |
| CN118146306A (zh) * | 2013-09-25 | 2024-06-07 | 西托姆克斯治疗公司 | 基质金属蛋白酶底物和其它可切割部分及其使用方法 |
| US9540440B2 (en) | 2013-10-30 | 2017-01-10 | Cytomx Therapeutics, Inc. | Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof |
| US9737623B2 (en) | 2013-12-11 | 2017-08-22 | Cytomx Therapeutics, Inc. | Antibodies that bind activatable antibodies and methods of use thereof |
| JP6835586B2 (ja) | 2014-01-31 | 2021-02-24 | シトムクス セラピューティクス，インコーポレイティド | マトリプターゼ及びｕ‐プラスミノーゲン活性化因子の基質及び他の切断可能部分、並びにその使用方法 |
| BR112017001579A2 (pt) | 2014-07-25 | 2017-11-21 | Cytomx Therapeutics Inc | anticorpos anti-cd3, anticorpos anti-cd3 ativáveis, anticorpos anti-cd3 multiespecíficos, anticorpos anti-cd3 ativáveis multiespecíficos e métodos de uso dos mesmos |
| WO2016028805A1 (en) * | 2014-08-18 | 2016-02-25 | Adrastia Biotech | Systems and methods of detecting solid tumor cancer |
| ES2789351T3 (es) * | 2015-01-13 | 2020-10-26 | Hope City | Máscaras de enlace peptídico de proteínas de unión a CTLA4 |
| MA41374A (fr) * | 2015-01-20 | 2017-11-28 | Cytomx Therapeutics Inc | Substrats clivables par métalloprotéase matricielle et clivables par sérine protéase et procédés d'utilisation de ceux-ci |
| CA2978942A1 (en) | 2015-03-13 | 2016-09-22 | Cytomx Therapeutics, Inc. | Anti-pdl1 antibodies, activatable anti-pdl1 antibodies, and methods of use thereof |
| CN107849133B (zh) | 2015-05-04 | 2022-08-23 | 西托姆克斯治疗公司 | 抗cd166抗体、可活化抗cd166抗体及其使用方法 |
| HUE050750T2 (hu) | 2015-05-29 | 2021-01-28 | Agenus Inc | CTLA-4 elleni antitestek és eljárások alkalmazásukra |
| EP3310811B1 (en) | 2015-06-16 | 2021-06-16 | Genentech, Inc. | Anti-cd3 antibodies and methods of use |
| EP3313874B1 (en) * | 2015-06-26 | 2021-03-10 | University of Southern California | Masking chimeric antigen receptor t cells for tumor-specific activation |
| CN106519037B (zh) * | 2015-09-11 | 2019-07-23 | 科济生物医药（上海）有限公司 | 可活化的嵌合受体 |
| JP7073258B2 (ja) | 2015-11-19 | 2022-05-23 | レビトープ リミテッド | 望ましくない細胞の再指向性死滅に対する二成分系のための機能的抗体断片相互補完 |
| SG11201806134SA (en) | 2016-01-27 | 2018-08-30 | Oncorus Inc | Oncolytic viral vectors and uses thereof |
| US10358496B2 (en) | 2016-03-01 | 2019-07-23 | Ralf Kleef | Low dose immune checkpoint blockade in metastatic cancer |
| WO2017177115A1 (en) | 2016-04-08 | 2017-10-12 | Massachusetts Institute Of Technology | Methods to specifically profile protease activity at lymph nodes |
| US11428689B2 (en) | 2016-05-05 | 2022-08-30 | Massachusetts Institute Of Technology | Methods and uses for remotely triggered protease activity measurements |
| EA201991383A1 (ru) | 2016-12-07 | 2019-12-30 | Эйдженус Инк. | Антитела против ctla-4 и способы их применения |
| KR102603681B1 (ko) | 2016-12-07 | 2023-11-17 | 아게누스 인코포레이티드 | 항체 및 이의 사용방법 |
| CN110036034A (zh) | 2016-12-09 | 2019-07-19 | 西雅图遗传学公司 | 卷曲螺旋掩蔽的二价抗体 |
| AU2018248327B2 (en) | 2017-04-07 | 2024-10-10 | Massachusetts Institute Of Technology | Methods to spatially profile protease activity in tissue and sections |
| KR20200016899A (ko) | 2017-06-01 | 2020-02-17 | 싸이톰스 테라퓨틱스, 인크. | 활성화가능 항-pdl1 항체, 및 이의 이용 방법 |
| BR112020000766A2 (pt) | 2017-07-14 | 2020-07-21 | Cytomx Therapeutics, Inc. | anticorpos anti-cd166 e seus usos |
| US11612625B2 (en) | 2017-07-26 | 2023-03-28 | Oncorus, Inc. | Oncolytic viral vectors and uses thereof |
| BR112020007309A2 (pt) | 2017-10-14 | 2020-09-29 | Cytomx Therapeutics, Inc. | anticorpos, anticorpos ativáveis, anticorpos biespecíficos e anticorpos ativáveis biespecíficos e métodos de uso dos mesmos |
| CA3083946A1 (en) | 2017-12-01 | 2019-06-06 | Seattle Genetics, Inc. | Cd47 antibodies and uses thereof for treating cancer |
| AR115360A1 (es) | 2018-02-08 | 2021-01-13 | Genentech Inc | Moléculas de unión al antígeno y métodos de uso |
| US11054428B2 (en) | 2018-03-05 | 2021-07-06 | Massachusetts Institute Of Technology | Inhalable nanosensors with volatile reporters and uses thereof |
| US20210020264A1 (en) | 2018-03-20 | 2021-01-21 | Cytomx Therapeutics, Inc. | Systems and methods for quantitative pharmacological modeling of activatable antibody species in mammalian subjects |
| JP7497340B2 (ja) | 2018-05-14 | 2024-06-10 | ウェアウルフ セラピューティクス， インコーポレイテッド | 活性化可能なインターロイキン１２ポリペプチド及びその使用方法 |
| FI3794024T3 (fi) | 2018-05-14 | 2023-08-10 | Werewolf Therapeutics Inc | Aktivoitavia interleukiini-2-polypeptidejä ja niiden käyttömenetelmiä |
| US20210322508A1 (en) * | 2018-08-13 | 2021-10-21 | Signablok, Inc. | Peptides and compositions for targeted treatment and imaging |
| US12173349B2 (en) | 2018-09-25 | 2024-12-24 | Massachusetts Institute Of Technology | Lung protease nanosensors and uses thereof |
| US12331320B2 (en) | 2018-10-10 | 2025-06-17 | The Research Foundation For The State University Of New York | Genome edited cancer cell vaccines |
| AU2019394972A1 (en) | 2018-12-06 | 2021-06-03 | Cytomx Therapeutics, Inc. | Matrix metalloprotease-cleavable and serine or cysteine protease-cleavable substrates and methods of use thereof |
| CN113490688B (zh) | 2018-12-26 | 2025-07-29 | 希望之城公司 | 可活化的被掩蔽的抗ctla4结合蛋白质 |
| EP3911753A1 (en) | 2019-01-17 | 2021-11-24 | Massachusetts Institute of Technology | Sensors for detecting and imaging of cancer metastasis |
| EP3969035A4 (en) | 2019-05-14 | 2023-06-21 | Werewolf Therapeutics, Inc. | SEPARATION UNITS AND METHODS AND THEIR USE |
| IL322315A (en) | 2019-05-14 | 2025-09-01 | Provention Bio Inc | Methods and preparations for preventing type 1 diabetes |
| WO2020236679A1 (en) * | 2019-05-17 | 2020-11-26 | Cytomx Therapeutics, Inc. | Methods and compositions for determining the biodistribution of activatable anti-cd166 antibody conjugates |
| WO2020247574A1 (en) | 2019-06-05 | 2020-12-10 | Seattle Genetics, Inc. | Methods of purifying masked antibodies |
| TW202112354A (zh) | 2019-06-05 | 2021-04-01 | 美商西雅圖遺傳學公司 | 遮蔽抗體調配物 |
| MX2022005666A (es) | 2019-11-14 | 2022-10-07 | Werewolf Therapeutics Inc | Polipeptidos de citocina activables y metodos de uso de los mismos. |
| US11845799B2 (en) | 2019-12-13 | 2023-12-19 | Genentech, Inc. | Anti-Ly6G6D antibodies and methods of use |
| WO2021207657A1 (en) | 2020-04-09 | 2021-10-14 | Cytomx Therapeutics, Inc. | Compositions containing activatable antibodies |
| MX2022015872A (es) | 2020-06-11 | 2023-05-16 | Provention Bio Inc | Metodos y composiciones para prevenir diabetes tipo 1. |
| CN111830254B (zh) * | 2020-07-29 | 2022-07-26 | 武汉生之源生物科技股份有限公司 | 一种基质金属蛋白酶-3测定试剂盒及其制备方法 |
| CN114859042B (zh) * | 2021-02-03 | 2023-11-03 | 广东菲鹏生物有限公司 | 一种鉴别结合突变型抗原的抗体的方法及试剂 |
| US20240352080A1 (en) | 2021-07-14 | 2024-10-24 | Seagen Inc. | Antibody Masking Domains |
| US20250116658A1 (en) * | 2021-07-26 | 2025-04-10 | Georgia Tech Research Corporation | Compositions and methods for in vivo protease profiling by immune cell display |
| US20240384323A1 (en) * | 2021-08-30 | 2024-11-21 | Cytomx Therapeutics, Inc. | Method for determining protease activity in a biological sample |
| US20240376200A1 (en) | 2021-09-24 | 2024-11-14 | Seagen Inc. | Improved Antibody Masking Domains |
| WO2023168239A2 (en) * | 2022-03-01 | 2023-09-07 | The Board Of Regents Of The University Of Texas System | Methods for identifying lilrb ligands and blocking antibodies |
| EP4508086A1 (en) | 2022-04-13 | 2025-02-19 | Genentech, Inc. | Pharmaceutical compositions of mosunetuzumab and methods of use |
| WO2025240659A2 (en) | 2024-05-14 | 2025-11-20 | Cytomx Therapeutics, Inc. | Activatable constructs, compositions and methods |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001091798A2 (en) | 2000-06-01 | 2001-12-06 | Universite Catholique De Louvain | Tumor activated prodrug compounds |
| US7465790B2 (en) | 2000-10-09 | 2008-12-16 | Isis Innovation, Inc. | Therapeutic antibodies |
| JP4334866B2 (ja) | 2000-10-09 | 2009-09-30 | アイシス イノヴェイション リミテッド | 治療用抗体 |
| US20040109855A1 (en) | 2002-07-23 | 2004-06-10 | Herman Waldmann | Therapeutic antibodies with reduced side effect |
| WO2004021861A2 (en) | 2002-09-03 | 2004-03-18 | Vit Lauermann | Targeted release |
| EP3896076A1 (en) | 2005-08-31 | 2021-10-20 | The Regents of the University of California | Cellular libraries of peptide sequences (clips) and methods of using the same |
| CA2645347A1 (en) | 2006-03-10 | 2007-09-20 | Diatos | Anticancer drugs conjugated to antibody via an enzyme cleavable linker |
| US9156914B2 (en) * | 2006-12-19 | 2015-10-13 | Ablynx N.V. | Amino acid sequences directed against a metalloproteinase from the ADAM family and polypeptides comprising the same for the treatment of ADAM-related diseases and disorders |
| WO2009014726A1 (en) | 2007-07-26 | 2009-01-29 | The Regents Of The University Of California | Methods for enhancing bacterial cell display of proteins and peptides |
| US20090304719A1 (en) | 2007-08-22 | 2009-12-10 | Patrick Daugherty | Activatable binding polypeptides and methods of identification and use thereof |
| WO2010077643A1 (en) | 2008-12-08 | 2010-07-08 | Tegopharm Corporation | Masking ligands for reversible inhibition of multivalent compounds |
| US20110178279A1 (en) * | 2009-08-03 | 2011-07-21 | Williams John C | Development of masked therapeutic antibodies to limit off-target effects: application to anti-egfr antibodies |
| CA2749339A1 (en) | 2009-01-12 | 2010-07-15 | Cytomx Therapeutics, Llc | Modified antibody compositions, methods of making and using thereof |
| US9309325B2 (en) | 2009-05-07 | 2016-04-12 | The Regents Of The University Of California | Antibodies and methods of use thereof |
| IN2014MN02164A (OSRAM) | 2012-04-27 | 2015-08-28 | Cytomx Therapeutics Inc | |
| SG11201408554QA (en) * | 2012-06-22 | 2015-02-27 | Cytomx Therapeutics Inc | Anti-jagged 1/jagged 2 cross-reactive antibodies, activatable anti-jagged antibodies and methods of use thereof |
| HK1210831A1 (en) | 2013-01-04 | 2016-05-06 | Cytomx Therapeutics Inc. | Compositions and methods for detecting protease activity in biological systems |
-
2014
- 2014-01-03 HK HK15111420.0A patent/HK1210831A1/xx unknown
- 2014-01-03 US US14/147,324 patent/US10261083B2/en active Active
- 2014-01-03 CA CA2896282A patent/CA2896282C/en active Active
- 2014-01-03 JP JP2015551784A patent/JP6605957B2/ja active Active
- 2014-01-03 RU RU2015132436A patent/RU2015132436A/ru unknown
- 2014-01-03 EP EP14735246.2A patent/EP2941643A4/en active Pending
- 2014-01-03 AU AU2014204015A patent/AU2014204015A1/en not_active Abandoned
- 2014-01-03 CN CN201480011969.7A patent/CN105008918A/zh active Pending
- 2014-01-03 CN CN202010717082.7A patent/CN112162094A/zh active Pending
- 2014-01-03 WO PCT/US2014/010216 patent/WO2014107599A2/en not_active Ceased
-
2018
- 2018-10-18 AU AU2018250437A patent/AU2018250437B2/en active Active
-
2019
- 2019-02-15 US US16/277,497 patent/US11035859B2/en active Active
- 2019-10-17 JP JP2019190445A patent/JP7001652B2/ja active Active
-
2021
- 2021-04-30 US US17/246,167 patent/US11867695B2/en active Active
- 2021-12-23 JP JP2021209234A patent/JP7223832B2/ja active Active
-
2023
- 2023-11-09 US US18/506,072 patent/US20240337658A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016505138A5 (OSRAM) | ||
| RU2015132436A (ru) | Способы обнаружения активности протеазы в биологических системах и композиции для их осуществления | |
| Guerrero et al. | Mechanistic peptidomics: factors that dictate specificity in the formation of endogenous peptides in human milk | |
| US9772328B2 (en) | Bimolecular protease-based biosensor | |
| JP2016538240A5 (OSRAM) | ||
| CN106796222B (zh) | 针对tsh受体的自身抗体的检测 | |
| Hoshijima et al. | Roles of heterotypic CCN2/CTGF–CCN3/NOV and homotypic CCN2–CCN2 interactions in expression of the differentiated phenotype of chondrocytes | |
| RU2011108943A (ru) | Профилактика, лечение и диагностика инфекции, вызванной бактериями p.gingivalis | |
| JP2017533181A5 (OSRAM) | ||
| Wang et al. | A fluorogenic peptide probe developed by in vitro selection using tRNA carrying a fluorogenic amino acid | |
| CN101842707A (zh) | 用于对选自bnp和bnp原的不稳定抗原定量的免疫测定法 | |
| Wang et al. | Further optimization of peptide substrate enhanced assay performance for BoNT/A detection by MALDI-TOF mass spectrometry | |
| SE0000675D0 (sv) | Monoclonal antibodies | |
| CN106568940A (zh) | 一种体外定量测定vWF‑CP酶活性的底物、方法及试剂盒 | |
| JP6624755B2 (ja) | プロテインタグ、タグ化タンパク質及びタンパク質精製方法 | |
| DE60219645D1 (de) | Antikörper gegen metastin und dessen verwendung zur diagnose von schwangerschaft | |
| Leung et al. | Osteopontin fragments with intact thrombin-sensitive site circulate in cervical cancer patients | |
| Mukherjee et al. | One-pot synthesis of heterodimeric agonists that activate the canonical Wnt signaling pathway | |
| WO2005103713A3 (en) | Methods, compositions and compound assays for inhibiting amyloid-beta protein production | |
| FR3001805A1 (fr) | Procede de detection d'un cancer colorectal | |
| JP2017037014A5 (OSRAM) | ||
| RU2005115973A (ru) | Растворимые субстраты на основе notch для гамма-секретазы, а также способы и композиции для их применения | |
| EP3362473B1 (en) | Use of a fibrinogen capture agent to detect a ciz1 b-variant | |
| Jägerbrink et al. | Proinsulin C-peptide interaction with protein tyrosine phosphatase 1B demonstrated with a labeling reaction | |
| CN112462074B (zh) | 一种cd277三种亚型蛋白的鉴定方法及检测试剂盒 |